$130.34
1.721.34%
Last update: Nov 4, 6:09 PM
Halozyme Therapeutics Inc (HALO) Stock Price, Quote, News & History
HALONASDAQ
Halozyme raised 2026 guidance, projected royalty revenue above $1B, and outlined long-term growth following strong ENHANZE momentum and acquisitions.
You can purchase shares of Halozyme Therapeutics (NASDAQ:HALO) through any online brokerage.
Other companies in Halozyme Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Halozyme Therapeutics has a consensus price target of $85.88.
The stock price for Halozyme Therapeutics (NASDAQ: HALO) is $131.1198 last updated November 4, 2026 at 6:09 PM EST.
There are no upcoming dividends for Halozyme Therapeutics.
Halozyme Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Halozyme Therapeutics.
Halozyme Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary...
